HRTX - Heron Therapeutics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
27.62
+1.42 (+5.42%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close26.20
Open26.37
Bid28.00 x 1300
Ask28.75 x 800
Day's Range26.33 - 27.78
52 Week Range20.05 - 42.90
Volume1,089,118
Avg. Volume845,965
Market Cap2.155B
Beta (3Y Monthly)1.15
PE Ratio (TTM)N/A
EPS (TTM)-2.82
Earnings DateNov 6, 2017 - Nov 10, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est51.83
Trade prices are not sourced from all markets
  • How Much Did Heron Therapeutics, Inc.’s (NASDAQ:HRTX) CEO Pocket Last Year?
    Simply Wall St.11 days ago

    How Much Did Heron Therapeutics, Inc.’s (NASDAQ:HRTX) CEO Pocket Last Year?

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Barry Quart became the CEO of Heron Read More...

  • PR Newswire12 days ago

    Heron Therapeutics Announces Retirement of Robert Rosen as President

    -Barry Quart, Pharm.D., Chief Executive Officer of Heron, to take on additional role of President- SAN DIEGO , Feb. 5, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology ...

  • ACCESSWIRE17 days ago

    Today's Research Reports on Trending Tickers: Mylan and Heron Therapeutics

    NEW YORK, NY / ACCESSWIRE / January 31, 2019 / U.S. equities regained footing on Wednesday as investors cheered the latest round of corporate earnings and the Federal Reserve kept the interest rates unchanged ...

  • GlobeNewswire18 days ago

    New Research Coverage Highlights Heron Therapeutics, IDACORP, Star Bulk Carriers, AngioDynamics, Marinus Pharmaceuticals, and Advaxis — Consolidated Revenues, Company Growth, and Expectations for 2019

    NEW YORK, Jan. 30, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • PR Newswirelast month

    Heron Therapeutics Highlights Progress in Pain Management and CINV Franchises

    - Acceptance of HTX-011 NDA for Postoperative Pain Management with Priority Review Designation; PDUFA Date of April 30, 2019 - - 90% of Patients Treated with HTX-011 Opioid-Free 72 Hours Post-Surgery in ...

  • PR Newswirelast month

    90% of Patients Remain Opioid-Free When HTX-011 Is Given with an Over-the-Counter Analgesic Regimen in New Multi-center Postoperative Pain Management Study

    SAN DIEGO, Jan. 3, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced results of a multi-center postoperative pain management study in which 63 patients undergoing hernia repair surgery received the investigational agent, HTX-011, together with a regimen of generic over-the-counter (OTC) oral analgesics (acetaminophen and ibuprofen). Designed as a follow-up to the Phase 3 study in hernia repair completed in 2018, this study included many of the same investigators and the same entry criteria as the Phase 3 study. The goal of the current study was to increase the proportion of opioid-free patients by combining HTX-011 with a regimen of readily available, oral analgesics.

  • Company News For Jan 2, 2019
    Zacks2 months ago

    Company News For Jan 2, 2019

    Companies In The News Are: BA,TXT,HRTX,GOOS,CWH

  • Heron Gains on Priority Review Designation for Pain Drug
    Zacks2 months ago

    Heron Gains on Priority Review Designation for Pain Drug

    Heron (HRTX) soars after the FDA accepted the company's NDA for pain drug, HTX-011, and granted Priority Review designation to the application.

  • PR Newswire2 months ago

    Heron Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference

    SAN DIEGO , Dec. 31, 2018 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments ...

  • MarketWatch2 months ago

    Heron stock up 4.3% after opioid alternative granted priority review designation from FDA

    Shares of Heron Therapeutics rose 4.5% in premarket trade Monday after the company announced the U.S. Food and Drug Administration had accepted the new drug application for its non-opioid alternative for post-operative pain management, granting it priority review designation. The product, dubbed HTX-011, is a combination of a long-acting, extended-release form of local anesthetic bupivacaine and the anti-inflammatory medication meloxicam. "We believe that HTX-011 could have a considerable impact on the lives of patients by significantly reducing the proportion of patients who experience severe pain and receive opioids after surgery, especially at discharge," said Heron Chief Executive Barry D. Quart in a statement. The FDA had previously granted breakthrough therapy status for HTX-011 based on the results of Phase 2 studies and two completed Phase 3 studies. Those studies showed the drug produced significant reductions in pain intensity and need for opioids compared to a placebo and bupivacaine alone. Shares of Heron have gained 31% this year, while shares of the iShares NASDAQ Biotechnology ETF have fallen 11%. The S&P 500 has fallen 7%.

  • PR Newswire2 months ago

    FDA Grants Priority Review Designation for Heron Therapeutics' NDA for HTX-011, a Non-Opioid for Postoperative Pain Management

    SAN DIEGO, Dec. 31, 2018 /PRNewswire/ -- Heron Therapeutics, Inc. (HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that the U.S. Food and Drug Administration (FDA) has accepted the new drug application (NDA) for Heron's investigational agent, HTX-011, and has granted it a Priority Review designation. HTX-011 is a long-acting, extended-release formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam for the management of postoperative pain.

  • Hedge Funds Are Buying Heron Therapeutics Inc (HRTX)
    Insider Monkey2 months ago

    Hedge Funds Are Buying Heron Therapeutics Inc (HRTX)

    A whopping number of 13F filings filed with U.S. Securities and Exchange Commission has been processed by Insider Monkey so that individual investors can look at the overall hedge fund sentiment towards the stocks included in their watchlists. These freshly-submitted public filings disclose money managers’ equity positions as of the end of the three-month period […]

  • ACCESSWIRE3 months ago

    Today's Research Reports on Trending Tickers: Heron Therapeutics and Supernus Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / November 29, 2018 / Wall Street closed up on Wednesday as dovish comments made by Federal Reserve Chairman Jerome Powell boosted investor optimism. According to the Chairman, Jerome Powell, “Interest rates are still low by historical standards, and they remain just below the broad range of estimates of the level that would be neutral for the economy — that is, neither speeding up nor slowing down growth.” The Dow Jones Industrial Average surged 2.5 percent to close at 25,366.43, while the S&P 500 Index jumped 2.3 percent to close at 2,743.79. “Markets wanted to hear Powell say that there is no preset course of rates, that he is mindful of weaknesses in the global economy, and, most importantly, that tariffs have altered the calculus of the future of the U.S. economy,” Cox said.

  • GlobeNewswire3 months ago

    Report: Exploring Fundamental Drivers Behind Aclaris Therapeutics, Extreme Networks, Care, Air Lease, Globus Medical, and Heron Therapeutics — New Horizons, Emerging Trends, and Upcoming Developments

    NEW YORK, Nov. 27, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • ACCESSWIRE3 months ago

    Today's Research Reports on Trending Tickers: Cronos Group and Heron Therapeutics

    NEW YORK, NY / ACCESSWIRE / November 26, 2018 / U.S. equities lost footing on Friday amidst drop in oil prices and selloff in FAANG (Facebook, Amazon, Apple, Netflix and Google-parent Alphabet) stocks. ...

  • When Will Heron Therapeutics Inc (NASDAQ:HRTX) Become Profitable?
    Simply Wall St.3 months ago

    When Will Heron Therapeutics Inc (NASDAQ:HRTX) Become Profitable?

    Heron Therapeutics Inc’s (NASDAQ:HRTX): Heron Therapeutics, Inc., a biotechnology company, engages in developing medicines to address unmet medical needs. The US$2.1b market-cap company’s loss lessens since it announced a -US$197.5m Read More...

  • PR Newswire3 months ago

    Heron Therapeutics to Present at the Evercore ISI HealthCONx Conference

    SAN DIEGO , Nov. 20, 2018 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments ...

  • U.S. Surgeon General Jerome Adams Discusses Opioid Alternatives and the Importance of Partnerships at Heron Therapeutics
    PR Newswire3 months ago

    U.S. Surgeon General Jerome Adams Discusses Opioid Alternatives and the Importance of Partnerships at Heron Therapeutics

    SAN DIEGO, Nov. 12, 2018 /PRNewswire/ -- Heron Therapeutics, Inc. (HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today hosted a fireside chat with the U.S. Surgeon General, Vice Admiral Jerome M. Adams, M.D., M.P.H. It was a familiar venue for Dr. Adams, as he continues to visit communities across the country and advocate for forming non-traditional partnerships with businesses, faith-based communities and law enforcement agencies to tackle the opioid crisis. During their meeting with the Surgeon General, Heron leaders and staff discussed the need for new and innovative opioid-free postoperative pain control, as well as the ways that science can help the nation find newer and smarter ways out of an epidemic that resulted in more than 42,000 opioid overdose deaths in 2016 according to data from the Centers for Disease Control and Prevention.

  • ACCESSWIRE3 months ago

    Today's Research Reports on Trending Tickers: Heron Therapeutics and Bristol-Myers Squibb

    According to Willie Delwiche, investment strategist at R.W. Baird, “Oil being down could be a sign that the global economy is in a tough spot.” “The initial reaction to lower oil prices has been that they’ll be a boon for the middle class,” Delwiche said that the view could be inaccurate considering that consumer confidence doesn’t have more chances to grow, and because a smaller part of the American consumer’s budget goes to gasoline than it has in the previous years. The stock recorded a trading volume of 1,456,948 shares, which was above its three months average volume of 998,535 shares. On Friday, shares of Bristol-Myers Squibb recorded a trading volume of 8,107,392 shares, which was above the three months average volume of 7,213,656 shares.

  • Heron Therapeutics (HRTX) Reports Q3 Loss, Tops Revenue Estimates
    Zacks3 months ago

    Heron Therapeutics (HRTX) Reports Q3 Loss, Tops Revenue Estimates

    Heron Therapeutics (HRTX) delivered earnings and revenue surprises of -4.26% and 6.31%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press3 months ago

    Heron Therapeutics: 3Q Earnings Snapshot

    On a per-share basis, the San Diego-based company said it had a loss of 49 cents. The results missed Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment Research ...

  • PR Newswire3 months ago

    Heron Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2018 and Recent Corporate Progress

    - Heron Raises Full-Year 2018 CINV Franchise Net Product Sales Guidance to $70 Million to $72 Million - SAN DIEGO , Nov. 7, 2018 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage ...

  • PR Newswire4 months ago

    Heron Announces FDA Submission of HTX-011 NDA for Postoperative Pain Management

    SAN DIEGO, Oct. 31, 2018 /PRNewswire/ -- Heron Therapeutics, Inc. (HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced the submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for HTX-011. HTX-011 is an investigational, long-acting, extended-release formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam for the management of postoperative pain. HTX-011 was granted both Breakthrough Therapy and Fast Track designations from the FDA.

  • Cramer's lightning round: If you want to invest in non-op...
    CNBC Videos4 months ago

    Cramer's lightning round: If you want to invest in non-op...

    Jim Cramer flies through his take on callers' favorite stocks, including that of a biotechnology company developing non-opioid pain medication.